Microinvasive cervical squamous cell carcinoma

Summary

Microinvasive cervical squamous cell carcinoma (MONDO:0004552) is a cancer and 2 clinical trials. Top therapeutic interventions include cisplatin and buparlisib. A subtype of cervical squamous cell carcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 2

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	microinvasive cervical squamous cell carcinoma
Mondo ID	MONDO:0004552
DOID	DOID:8409
NCIT	C36094
UMLS	C1333370
MedGen	272565
GARD	0024064
Is cancer (heuristic)	yes

Also known as: early invasive cervical squamous cell carcinoma

Disease family

This is a subtype of cervical squamous cell carcinoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › epithelial neoplasm › squamous cell neoplasm › squamous cell carcinoma › cervical squamous cell carcinoma › microinvasive cervical squamous cell carcinoma

Related subtypes (6): cervical verrucous carcinoma, cervical basaloid carcinoma, cervical keratinizing squamous cell carcinoma, cervical lymphoepithelioma-like carcinoma, cervical non-keratinizing squamous cell carcinoma, cervical adenosquamous carcinoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 2.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE1	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02113878	PHASE1	COMPLETED	Phase Ib Study of BKM120 With Cisplatin and XRT in High Risk Locally Advanced Squamous Cell Cancer of Head and Neck
NCT02140021	Not specified	TERMINATED	Biospecimen Collection and Testing for the Prevalence of Anal Dysplasia and Anal Cancer in Patients With Cervical, Vaginal and Vulvar Dysplasia and Cancer

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
CISPLATIN	4	1
BUPARLISIB	3	1